Posted in News
To help users better understand brand-level medicines use, we have separated the concepts of ‘brand’ and ‘actual generic’, allowing us to align with both dm+d and ePACT data concepts. This means that a brand or generic product can be specified without having to select from several different sources.
For example, ‘Epilim Chrono 200 tablets’ has six actual products (AMPs) listed in dm+d (manufacturers, wholesalers and parallel importers) but the new concept will allow mapping to Epilim Chrono 200 tablets without the requirement to select one of the six listed suppliers.
This means Trusts will be better able to compare the costs and relative use of actual products and be able to drive cost-effective purchasing.